Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases. The company builds its pipeline by acquiring or in-licensing product candidates. Climb Bio, Inc. develops its product candidates for multiple immune-mediated diseases. The company acquired the rights to its product candidates through license and asset purchase agreements. Climb Bio, Inc. holds worldwide rights to develop and commercialize budoprutug for all indications, excluding oncology. For CLYM116, the company has rights to develop and commercialize it for all indications worldwide, except for mainland China, Hong Kong, Macau, and Taiwan, collectively referred to as Greater China. The lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. CD19 is involved in B-cell development, and clinical evidence supports its role in immune-mediated diseases. Budoprutug aims to reduce B cells and pathogenic autoantibodies, potentially offering a disease-modifying therapeutic approach. Climb Bio, Inc. is initially developing budoprutug for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Primary membranous nephropathy is a rare, immune-mediated renal disease where autoantibodies cause proteinuria, nephrotic syndrome, and progressive kidney function loss. These autoantibodies are primarily secreted by plasmablasts that express CD19 but largely lack CD20. Early clinical data supports targeting CD19-selective depletion in pMN, and with no approved therapies, budoprutug may offer a treatment option. ITP is a rare autoimmune disorder characterized by antibody-mediated platelet destruction, leading to bruising, bleeding, hemorrhage, and fatigue.